Dublin, Nov. 07, 2025 (GLOBE NEWSWIRE) — The “Premenstrual Syndrome Treatment Market Report by Drug Type, Type, Distribution Channel, Countries and Company Analysis 2025-2033” has been added to ResearchAndMarkets.com’s offering.
The Premenstrual Syndrome (PMS) Treatment Market will expand from US$ 1.38 billion in 2024 to US$ 1.90 billion by 2033, growing at a CAGR of 3.63% over the forecast period 2025-2033. The growth is fueled by escalating awareness about women’s health, growing incidence of PMS symptoms, advances in hormonal and non-hormonal therapies, and expansion in demand for effective treatments in global healthcare markets.
Drivers of Growth in the Premenstrual Syndrome Treatment Market
Increased Awareness and Education on Women’s Health
One major driver of the PMS treatment market is growing global awareness regarding women’s health. Increased health education, social media campaigns, and government initiatives help women understand their PMS symptoms and the available treatments. Educational campaigns lead to early medical consultancy, increasing the adoption rate of pharmaceutical as well as non-pharmaceutical treatments. Women are increasingly looking to medical professionals for moderate to severe symptoms of PMS, driving global demand for successful therapies. As many as 75% of women, according to the National Institutes of Health (NIH), suffer from some symptom of premenstrual syndrome (PMS), with about 5% of women experiencing severe cases that interfere with daily life, which is referred to as Premenstrual Dysphoric Disorder (PMDD).
Pharmaceutical and Non-Pharmaceutical Treatments Advances
Ongoing advancements in hormonal therapies, antidepressants, NSAIDs, and nutritional supplements are fueling market growth. Breakthroughs in selective serotonin reuptake inhibitors (SSRIs) and combination oral contraceptives are achieving good symptom control. At the same time, increased popularity of herbal treatments and lifestyle-based therapies makes treatments more accessible. The presence of various therapies enables practitioners to provide customized treatment plans, increasing patient satisfaction and overall market growth. September 2023: Vistagen, a clinical stage biopharmaceutical company, reported encouraging data from an exploratory Phase 2A study of PH80 for acute treatment of premenstrual dysphoric disorder (PMDD) symptoms, including negative mood along with physical and behavioral symptoms.
Increasing Healthcare Access and Urbanization
The development of healthcare infrastructure in emerging economies, allied with urbanization, has increased the accessibility of PMS treatments. Women living in urban areas have higher exposure to medical centers, awareness programs, and pharmacies that sell over-the-counter and prescription medication. Coverage by insurance companies and telemedicine platforms further enhance access to treatment, and more women are able to access medical advice. All these factors combined support strong growth in the global PMS treatment market.
Challenges of the Premenstrual Syndrome Treatment Market
Limited Diagnosis and Awareness in Developing Regions
Even with advancements, PMS continues to be underdiagnosed in most areas, especially rural and poverty-stricken communities. Cultural taboos, unawareness, and the scarcity of gynecological care keep women from visiting medical facilities. Such underdiagnosis limits the overall market size for PMS treatment. Companies are also constrained from bringing sophisticated treatments to underserved areas by poor healthcare infrastructure and low expenditure capacities.
Side Effects and Compliance Problems with Treatment Options
Pharmaceutical therapies, such as SSRIs, hormonal contraceptives, and NSAIDs, have side effects like weight gain, nausea, or mood swings. These possible adverse effects sometimes discourage patient compliance, influencing the effectiveness of treatment. In addition, the chronic character of PMS symptoms demands regular treatment, and poor compliance results in suboptimal results. Non-pharmaceutical therapy, while safer, will have limited efficacy, showing the demand for better-tolerated, improved treatments to promote market growth.
Analgesics Premenstrual Syndrome Treatment Market
Analgesics are instrumental in PMS treatment, giving quick relief from body pain, cramps, and headaches. NSAIDs such as ibuprofen and naproxen are popular over-the-counter drugs because of their easy availability and affordability. The segment remains on the rise with women preferring fast-acting, non-prescription drugs for mild to moderate PMS symptoms. Pharmaceutical firms are increasing product availability through retail and e-commerce platforms, fueling demand in the market.
Prescription Premenstrual Syndrome Treatment Market
The prescription PMS treatment market is fueled by hormonal therapies, SSRIs, and diuretics for treating severe symptoms or premenstrual dysphoric disorder (PMDD). Doctors favor prescription drugs for patients showing notable mood or physical disruption. Rising awareness of PMDD and the growth in women’s health clinics improve market opportunities. Ongoing innovation in safer and more effective prescription medications further solidifies this market segment.
Premenstrual Syndrome Hospital Pharmacies Treatment Market
Hospital pharmacies are major distribution channels for prescription PMS treatments, particularly severe ones that need clinical assessments. Women who report to hospitals for gynecologic checkups tend to be prescribed directly by specialist physicians and have their prescriptions filled in-house at hospital pharmacies. This segment enjoys increasing hospital-based gynecology services, increasing awareness of PMDD, and the availability of specialist physicians. The presence of sophisticated medicines in hospitals also enhances market growth.
Key Attributes
| Report Attribute | Details |
| No. of Pages | 200 |
| Forecast Period | 2024 – 2033 |
| Estimated Market Value (USD) in 2024 | $1385.44 Million |
| Forecasted Market Value (USD) by 2033 | $1909.67 Million |
| Compound Annual Growth Rate | 3.6% |
| Regions Covered | Global |
Key Topics Covered
1. Introduction
2. Research & Methodology
3. Executive Summary
4. Market Dynamics
4.1 Growth Drivers
4.2 Challenges
5. Global Premenstrual Syndrome Treatment Market
5.1 Historical Market Trends
5.2 Market Forecast
6. Market Share Analysis
6.1 By Drug Type
6.2 By Type
6.3 By Distribution Channel
6.4 By Countries
7. Drug Types
7.1 Analgesics
7.2 Antidepressants
7.3 Oral Contraceptives and Ovarian Suppression Agents
7.4 Others
8. Types
8.1 Prescription
8.2 Over-the-Counter
9. Distribution Channels
9.1 Hospital Pharmacies
9.2 Drug Stores and Retail Pharmacies
9.3 Online Stores
10. Countries
10.1 North America
10.2 Europe
10.3 Asia Pacific
10.4 Latin America
10.5 Middle East & Africa
11. Value Chain Analysis
12. Porter’s Five Forces Analysis
12.1 Bargaining Power of Buyers
12.2 Bargaining Power of Suppliers
12.3 Degree of Competition
12.4 Threat of New Entrants
12.5 Threat of Substitutes
13. SWOT Analysis
13.1 Strength
13.2 Weakness
13.3 Opportunity
13.4 Threats
14. Pricing Benchmark Analysis
15. Key Players Analysis
15.1 AbbVie Inc.
15.2 BASF SE
15.3 Bayer AG
15.4 Dr. Reddy’s Laboratories Ltd
15.5 Eli Lilly and Company
15.6 GlaxoSmithKline PLC
15.7 H. Lundbeck A/S
15.8 Pfizer Inc.
15.9 SHIONOGI & Co. Ltd.
For more information about this report visit https://www.researchandmarkets.com/r/rwdu4t
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
- Premenstrual Syndrome Treatment Market
